Delivery Order SPE2DB20D2104-SPE2DB22FR80V
- Not listed
- This federal contract award, valued at $12,938.26, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,658.63, is for the delivery of Xifaxan 550 mg tablets. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical, valued at up to $999,999,999.00. This IDC serves as the primary vehicle for...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,691.88, is for the delivery of Xifaxan 550 mg tablets. This is a Delivery Order contract with a Firm Fixed Price pricing type, with a completion date of December 6, 2023. The contract is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora,...
- This federal contract award, valued at $8,139.55, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Xifaxan 550 mg tablets and is a firm fixed-price Delivery Order. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The $7,918.17 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The award, valued at $37,247.17, is for the delivery of Xifaxan 550 mg tablets. The contract has a period of performance through September 27, 2023 and is a firm fixed-price delivery order. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,406.52 delivery order is for the supply of Xifaxan 550 mg tablets. The contract is a firm fixed-price Delivery Order under a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Amerisourcebergen's parent company, Cencora, Inc. This IDC, valued at up to $999,999,999.00, serves as a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xifaxan 550 mg tablets. The $1,992.03 Firm Fixed Price delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Cencora, Inc. to...
- This federal contract award, valued at $18,142.68, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Xifaxan 550 mg tablets, a prescription medication used to treat various gastrointestinal conditions. The award is a delivery order under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a ceiling value of $999,999,999 and runs through...
- This federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical is for the delivery of Xifaxan 550 mg tablets to support military and veterans' healthcare programs. The $8,613.32 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB22FR80VDelivery Order
This federal contract award, valued at $23,835.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of Xifaxan 550 mg tablets. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, worth up to $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have any set-aside designation, indicating open competition. Amerisourcebergen, a major pharmaceutical distributor, plays a critical role in supplying essential medical products to federal government agencies, including the Department of Defense and Department of Veterans Affairs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.8k | 2/11/22 |